AU2009266430B2 - Anti- P2X7 peptides and epitopes - Google Patents

Anti- P2X7 peptides and epitopes Download PDF

Info

Publication number
AU2009266430B2
AU2009266430B2 AU2009266430A AU2009266430A AU2009266430B2 AU 2009266430 B2 AU2009266430 B2 AU 2009266430B2 AU 2009266430 A AU2009266430 A AU 2009266430A AU 2009266430 A AU2009266430 A AU 2009266430A AU 2009266430 B2 AU2009266430 B2 AU 2009266430B2
Authority
AU
Australia
Prior art keywords
antibody
peptide
residues
region
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009266430A
Other languages
English (en)
Other versions
AU2009266430A1 (en
AU2009266430A8 (en
Inventor
Julian Alexander Barden
Angus Gidley-Baird
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosceptre International Ltd
Original Assignee
Biosceptre International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008903451A external-priority patent/AU2008903451A0/en
Application filed by Biosceptre International Ltd filed Critical Biosceptre International Ltd
Priority to AU2009266430A priority Critical patent/AU2009266430B2/en
Publication of AU2009266430A1 publication Critical patent/AU2009266430A1/en
Publication of AU2009266430A8 publication Critical patent/AU2009266430A8/en
Application granted granted Critical
Publication of AU2009266430B2 publication Critical patent/AU2009266430B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2009266430A 2008-07-04 2009-07-03 Anti- P2X7 peptides and epitopes Active AU2009266430B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009266430A AU2009266430B2 (en) 2008-07-04 2009-07-03 Anti- P2X7 peptides and epitopes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2008903451A AU2008903451A0 (en) 2008-07-04 Composite peptide
AU2008903451 2008-07-04
AU2009266430A AU2009266430B2 (en) 2008-07-04 2009-07-03 Anti- P2X7 peptides and epitopes
PCT/AU2009/000869 WO2010000041A1 (en) 2008-07-04 2009-07-03 Anti- p2x7 peptides and epitopes

Publications (3)

Publication Number Publication Date
AU2009266430A1 AU2009266430A1 (en) 2010-01-07
AU2009266430A8 AU2009266430A8 (en) 2011-03-10
AU2009266430B2 true AU2009266430B2 (en) 2014-08-14

Family

ID=41465424

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009266430A Active AU2009266430B2 (en) 2008-07-04 2009-07-03 Anti- P2X7 peptides and epitopes

Country Status (12)

Country Link
US (3) US8597643B2 (OSRAM)
EP (1) EP2318438B1 (OSRAM)
JP (2) JP5701752B2 (OSRAM)
KR (1) KR101701300B1 (OSRAM)
CN (1) CN102143978B (OSRAM)
AU (1) AU2009266430B2 (OSRAM)
BR (1) BRPI0915367B8 (OSRAM)
CA (1) CA2729868C (OSRAM)
ES (1) ES2610225T3 (OSRAM)
IL (2) IL210220A (OSRAM)
NZ (1) NZ590146A (OSRAM)
WO (1) WO2010000041A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1961767B1 (en) 2001-01-17 2012-03-07 Biosceptre International Limited Diagnosis and treatment of cancers and other conditions
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
EP2201377B1 (en) 2007-09-14 2012-01-18 Biosceptre International Limited Purinergic (p2x) receptors in extra-cellular body fluid
BRPI0915367B8 (pt) 2008-07-04 2021-05-25 Biosceptre International Ltd peptídeo anti-p2x7
ES2557456T3 (es) 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
JP5992831B2 (ja) 2009-12-24 2016-09-14 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 非機能性オリゴマーｐ２ｘ７受容体に対する抗体
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
CA2840251C (en) 2011-07-01 2023-09-12 Biosceptre International Limited Combination therapy of diseases that are associated with non-functional p2x7 receptor expression
AU2016240410B2 (en) * 2015-04-02 2021-09-16 Biosceptre (Aust) Pty Ltd Pain treatment
KR20180043841A (ko) 2015-09-11 2018-04-30 카리나 바이오테크 피티와이 엘티디 키메라 항원 수용체 및 이의 용도
WO2018071959A1 (en) 2016-10-21 2018-04-26 Biosceptre (Uk) Limited Cytotoxic particles
JP2024513485A (ja) * 2021-04-08 2024-03-25 バイオセプター （オースト） プロプライエタリー・リミテッド 免疫細胞活性を制御する方法
JP2025531021A (ja) * 2022-09-14 2025-09-19 バイオセプター （オースト） プロプライエタリー・リミテッド 免疫細胞を検出する方法
AU2023343788A1 (en) * 2022-09-14 2025-02-20 Biosceptre (Aust) Pty Ltd Enrichment of engineered immune cells
EP4587067A1 (en) * 2022-09-14 2025-07-23 Biosceptre (Aust) Pty Ltd In vivo detection of immune cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002047306A1 (en) * 2000-12-06 2002-06-13 Linex Technologies, Inc. Efficient sharing of capacity by remote stations using circuit switching and packet switching
WO2003020762A1 (en) * 2001-09-03 2003-03-13 Intreat Pty Limited Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
WO2008043145A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional p2x7 receptor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
JPH10501122A (ja) 1994-05-27 1998-02-03 グラクソ、グループ、リミテッド Ｐ▲下２ｘ▼レセプター（プリノセプターファミリー）
CA2228999A1 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
AU5506896A (en) 1996-04-30 1997-11-19 Human Genome Sciences, Inc. Human p2x4 receptor splice-variants
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
DE69941187D1 (de) 1998-06-01 2009-09-10 Agensys Inc Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
WO2001030964A2 (en) 1999-10-22 2001-05-03 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
EP1961767B1 (en) 2001-01-17 2012-03-07 Biosceptre International Limited Diagnosis and treatment of cancers and other conditions
DE602004007184T2 (de) 2003-04-17 2008-02-28 Affectis Pharmaceuticals Ag Mittel und Verfahren zur Diagnose und Behandlung affektiver Störungen
US20090215727A1 (en) 2005-05-05 2009-08-27 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphate and vitamin b6 related compounds
US7767789B2 (en) 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
WO2007027957A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
EP2201377B1 (en) 2007-09-14 2012-01-18 Biosceptre International Limited Purinergic (p2x) receptors in extra-cellular body fluid
BRPI0915367B8 (pt) 2008-07-04 2021-05-25 Biosceptre International Ltd peptídeo anti-p2x7
ES2557456T3 (es) 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
JP5992831B2 (ja) 2009-12-24 2016-09-14 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 非機能性オリゴマーｐ２ｘ７受容体に対する抗体
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
CA2840251C (en) 2011-07-01 2023-09-12 Biosceptre International Limited Combination therapy of diseases that are associated with non-functional p2x7 receptor expression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002047306A1 (en) * 2000-12-06 2002-06-13 Linex Technologies, Inc. Efficient sharing of capacity by remote stations using circuit switching and packet switching
WO2003020762A1 (en) * 2001-09-03 2003-03-13 Intreat Pty Limited Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
WO2008043145A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional p2x7 receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BARDEN, J.A., et al., "Specific detection of non-functional human P2X7 receptors in HEK293 cells and B-lymphocytes," FEBS Letters, 2003, Vol 538, pages 159-162 *

Also Published As

Publication number Publication date
US10238716B2 (en) 2019-03-26
WO2010000041A1 (en) 2010-01-07
CN102143978B (zh) 2015-02-18
KR20110031222A (ko) 2011-03-24
US9328155B2 (en) 2016-05-03
EP2318438B1 (en) 2016-11-02
AU2009266430A1 (en) 2010-01-07
US20160199442A1 (en) 2016-07-14
AU2009266430A8 (en) 2011-03-10
ES2610225T3 (es) 2017-04-26
BRPI0915367B8 (pt) 2021-05-25
JP2015038144A (ja) 2015-02-26
EP2318438A4 (en) 2012-11-21
CN102143978A (zh) 2011-08-03
US8597643B2 (en) 2013-12-03
JP2011526249A (ja) 2011-10-06
BRPI0915367B1 (pt) 2020-10-13
CA2729868A1 (en) 2010-01-07
EP2318438A1 (en) 2011-05-11
IL210220A0 (en) 2011-03-31
JP5701752B2 (ja) 2015-04-15
BRPI0915367A2 (pt) 2015-11-03
IL232394A (en) 2016-04-21
IL210220A (en) 2016-04-21
CA2729868C (en) 2018-07-10
US20140135475A1 (en) 2014-05-15
IL232394A0 (en) 2014-06-30
KR101701300B1 (ko) 2017-02-01
NZ590146A (en) 2012-09-28
US20110110959A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
AU2009266430B2 (en) Anti- P2X7 peptides and epitopes
US10597451B2 (en) Methods of treating cancer with a P2X7 peptide
ES2811274T3 (es) Anticuerpos monoclonales humanizados y quiméricos para CD99
EP1999153A1 (en) Agonist antibodies against tshr
CN114401744B (zh) 用于治疗癌症的抗cd33抗体
CN120329441A (zh) Cd33抗体和使用所述抗体治疗癌症的方法
CN114341176A (zh) Cd19抗体及其使用方法
KR20240040097A (ko) Cd3 표적화 항체 및 이의 용도
KR20230147624A (ko) 면역조절 항체 및 이의 용도
US9840560B2 (en) Monoclonal antibodies to EGFR, and uses therefor
TW202311293A (zh) 免疫療法之組合及其用途
EP4342914A1 (en) Anti-bcam antibody or antigen-binding fragment thereof
HK1152046B (en) Anti-p2x7 peptides and epitopes
HK1152046A (en) Anti-p2x7 peptides and epitopes
CN119505001B (zh) 靶向cd22的全人源抗体及其应用
EP1101495A1 (en) Preventives for idiopathic thrombocytopenic purpura
CN117062835A (zh) 免疫调节性抗体及其用途

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 25, NO 4, PAGE(S) 398 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME BIOSCEPTRE INTERNATIONAL LIMIITED, APPLICATION NO. 2009266430, UNDER INID (54) CORRECT THE TITLE TO ANTI- P2X7 PEPTIDES AND EPITOPES; UNDER INID (72) CORRECT THE NAME TO BIOSCEPTRE INTERNATIONAL LIMITED

FGA Letters patent sealed or granted (standard patent)